Page last updated: 2024-11-13
crolibulin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
crolibulin: a vascular disrupting agent with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23649181 |
| CHEMBL ID | 2103852 |
| CHEBI ID | 177518 |
| SCHEMBL ID | 1750575 |
| MeSH ID | M000606950 |
Synonyms (34)
| Synonym |
|---|
| 1000852-17-4 |
| CHEBI:177518 |
| (4r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile |
| crolibulin |
| D09882 |
| crolibulin (usan) |
| crolibulin [usan:inn] |
| 9ent43ky91 , |
| epc2407 |
| unii-9ent43ky91 |
| epc 2407 |
| CHEMBL2103852 |
| epc-2407 |
| crolibulin [usan] |
| crolibulin [who-dd] |
| crolibulin [inn] |
| SCHEMBL1750575 |
| DTXSID10142925 |
| 4h-1-benzopyran-3-carbonitrile, 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-, (4r)-;4h-1-benzopyran-3-carbonitrile, 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-, (4r)- |
| DB12925 |
| (r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile |
| HY-13603 |
| CS-0007407 |
| EX-A2452 |
| crolibulin; epc2407 |
| JXONINOYTKKXQQ-CQSZACIVSA-N |
| (r)-2,7,8-triamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene |
| (4r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-1-benzopyran-3-carbonitrile |
| bg0 , |
| epc2407; crinobulin |
| Q27272449 |
| MS-27274 |
| AC-36076 |
| AKOS040741574 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| neoflavonoid | Any 1-benzopyran with an aryl substituent at position 4. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1352574 | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. |
| AID1352573 | Antiproliferative activity against human H460 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. |
| AID1352572 | Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. |
| AID1352576 | Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. |
| AID1352575 | Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||